Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.Prescrire Int. 2003 Dec; 12(68):230-1.PI
(1) Of the four anticholinesterases available in France for the treatment of mild to moderate Alzheimer's disease, donepezil is the reference agent. (2) Yet even donepezil is only moderately effective: only about 10% of patients show a short-lived clinical improvement. (3) Recent systematic reviews from Cochrane and NICE confirm the moderate efficacy of anticholinesterases in this setting.